At Alithea Genomics we are committed to developing solutions that simplify and streamline the generation of `big RNA data`, which we believe will constitute the foundation of tomorrow`s research and medicine. Our technologies enable our clients to discover new biomarkers and develop new drugs at a fraction of the costs and time as compared to what was possible before. By leveraging BRB-seq, we not only provide to industrial and academic clients high quality RNA-seq data, but we also do so with the highest affordability and shortest turnaround times on the market.
Find locations served, office locations
- Business Type:
- Industry Type:
- Medical Monitoring
- Market Focus:
- Internationally (various countries)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
- Mercurius - Model BRB-seq - Library Preparation Kits for Illumina
- Mercurius - Model BRB-seq - Cell Lysate Extraction-Free Library Preparation Kits for Illumina
- Mercurius - Cell Lysate BRB-seq Service
- Mercurius - Organoid Lysate BRB-seq Service
- Mercurius - Model Blood BRB-seq - Library Preparation Kits for Illumina
Alithea (Greek): 'the state of not being hidden'. We like to think of it as 'the state of DISCOVERY'
From research to technology
Our story begins with a very concrete research need, i.e., to be able to run a large number of RNA sequencing experiments in an affordable and rapid manner.
To address this need, we set out to develop a new technology called Bulk RNA Barcoding and sequencing (BRB-seq). We published our technology in the peer-reviewed journal Genome Biology in April 2019 and, by the end of the year, our article entered the 2019 TOP 10 most read papers of the journal.
From BRB-seq to Alithea
As a corroboration of the interest of the scientific community, we received several inquiries from labs and companies asking for support to establish our technology in their facilities (kits) or to run BRB-seq directly on their RNA samples (service).
The demand grew rapidly, we seen a gap in the industry and so the decision was made to launch our own company.
Alithea Genomics was founded in May 2020 by co-founders Riccardo Dainese (CEO), Daniel Alpern (CTO) and Prof. Bart Deplancke (Scientific advisor).